A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs TDENV PIV (Primary) ; Aluminium hydroxide; AS01E; AS03B
- Indications Dengue
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Acronyms DPIV-001
- 04 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 04 Apr 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 30 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.